A. Saavedra

发表

Neutrophil-to-lymphocyte ratio predicts early mortality in females with metastatic triple-negative breast cancer

H. Gómez, J. Pinto, D. Chambergo-Michilot, 2020, PloS one.

Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience

H. Gómez, J. Pinto, J. Cotrina, 2020, PloS one.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Lymph node ratio as best prognostic factor in triple‐negative breast cancer patients with residual disease after neoadjuvant chemotherapy

H. Gómez, J. Pinto, J. Cotrina, 2020, The breast journal.

Post-recurrence survival in triple negative breast cancer.

H. Gómez, D. Enríquez, J. Pinto, 2018 .

Lenvatinib (Len) alone or in combination with everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience

E. Jonasch, M. Campbell, A. Shah, 2019, Annals of Oncology.

A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.

G. Lenaers, A. de Gramont, E. Gamelin, 2004, Bulletin du cancer.

Neutrophil-to-lymphocyte ratio as a predictor of early death in metastatic triple-negative breast cancer

H. Gómez, D. Enríquez, J. Pinto, 2020 .

Safety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment

T. Ho, M. Atkins, Siraj M. Ali, 2019, Annals of Oncology.